Objective-Growing insight into the antiplatelet properties of new nitric oxide (NO) donors has expanded their potential use in cardiovascular diseases. As such, we reported that oral administration of a new exogenous NO donor (LA419) induced significant inhibition of platelet deposition on damaged vascular wall without provoking hypotension in an in vivo experimental model. Thrombin is one of the major triggers of platelet deposition and thrombosis on injured vessels; however, the effects of NO on thrombin-induced platelet activation are not fully known. Here, our aim was to investigate the inhibitory effects of exogenous NO administration on the major changes in platelet proteins induced by thrombin. Methods and Results-Platelets were obtained from a group of swine orally treated with LA419 (0.9 mg kg Ϫ1 ) or placebo for 8 days. Washed platelets were incubated with thrombin (0.4 NIH U/mL). Platelet proteins were then sequentially extracted based on differential solubility and studied by two-dimensional electrophoresis, mass spectrometry (matrixassisted laser desorption ionization/time of flight), Western blot, and confocal immunofluorescence. NO treatment abrogated thrombin effects on 24 proteins involved in actin assembly, signaling, and metabolic activity. NO treatment prevented thrombin-induced translocation of gelsolin, filamin, 14-3-3, phosphatidylinositol 3-kinase-␥ isoform, and growth factor receptor-bound protein 2 (Grb2). Conclusion-Our results show that exogenous NO donor treatment renders platelets less sensitive to thrombin activation and inhibits thrombosis by interfering with the platelet shape change machinery. (Arterioscler Thromb Vasc Biol. 2011;31:2560-2569.)
P latelets are one of the main targets for drug development in the prevention and treatment of cardiovascular and cerebrovascular atherothrombosis. 1 Advances in the understanding of the mechanisms involved in platelet activation and aggregation have provided new avenues for drug development. 2, 3 Inactive platelets brought by the circulation are recruited to the site of vascular injury by the combined effects of a number of molecules (thrombin, collagen, fibrinogen, von Willebrand factor, ADP, thromboxane A2, epinephrine, and others) that trigger platelet signaling events and promote adhesion and aggregation. 4, 5 These signaling events arise from multimolecular complexes formed between integrin cytoplasmic tails, intracellular signaling molecules, and structural cytoskeleton proteins. 6 Nitric oxide (NO) released from platelets and endothelium under physiological conditions is involved in several vascular processes, including reduction of cytokine-induced expres-sion of tissue factor, 7 monocyte adhesion to the endothelium, vasodilation, and inhibition of platelet adhesion and aggregation. 8 -11 NO regulates platelet activation mainly through cGMP-dependent mechanisms. 12 NO-induced inhibition of platelet function has long been known; however, the signaling pathways underlying the inhibitory action of exogenous NO donors (NOds) on agonist-induced platelets are not yet fully characterized. Nitrovasodilators, including organic nitrates, are widely used for the treatment of patients with stable coronary artery disease, 13 primarily for their vasodilator effects, because their antiplatelet effects are weak and mainly observed at suprapharmacological doses commonly associated with hypotensive side effects. We have described the antiplatelet effects achieved after oral administration of an exogenous NOd 14 -a neutral sugar organic nitrate with a protected thiol-devoid of hemodynamic side effects at platelet inhibitory doses (LA419). We showed antithrombotic properties that exceeded those of IS-5-MN (a standard mononitrate) and reported that LA419 increased platelet cGMP levels. 14, 15 By means of a proteomic approach, here we aimed at expanding our understanding into the molecular mechanisms by which NO exerts its antiplatelet effects. As platelets are anucleated, activation is mainly controlled by translocation of proteins, altered interactions, and posttranslational modifications, such as phosphorylation and glycosylation. Whole platelet proteome in human 16 and swine platelets, 17 as well as several platelet subproteomes 15 of resting and stimulated platelets, have been analyzed. Studies examining protein changes, such as translocation in response to platelet stimulus, are highly helpful, as they allow the identification of key proteins in platelet function.
In this study, we examined protein changes in the cytosolic and membrane/cytoskeleton subproteomes of thrombinstimulated platelets from control and NOd-treated platelets. Our results show that oral treatment with a NOd, besides its antithrombotic effects, inhibits thrombin-induced translocation of the signaling proteins phosphatidylinositol 3-kinase (PI3K)-␥ isoform, growth factor receptor-bound protein 2 (Grb2), and 14-3-3, involved in preventing cytoskeletal rearrangements and consequently platelet shape change.
Materials and Methods
See supplemental materials, available online at http://atvb.ahajournals.org, for expanded Methods section.
Sample Preparation
Blood, collected in 14% acid citrate dextrose, was obtained from control (placebo-treated; nϭ4) and NO-treated (NOd treated; 0.9 mg/kg, BIP; nϭ4) female pigs after 8 days of oral treatment, as described. 14 This treatment regime inhibits platelet aggregation induced by high doses of potent agonists, such as collagen and ADP, and platelet deposition on damaged vessel wall under controlled flow conditions. 14 All procedures were in accordance with National Institutes of Health guidelines and followed the American Physiological Society Guidelines for animal research.
Washed platelets were incubated without or with thrombin (0.4 NIH U/mL) for 2 minutes at 37°C. Thrombin was chosen as the agonist because of its key importance in triggering thrombosis on severely damaged atherosclerotic vessels. 15 Platelet pellets were separated and frozen in liquid nitrogen until further use.
Protein Extraction and Proteomic Analysis
Frozen platelet pellets were sequentially extracted based on differential solubility. 18 A Tris-soluble (cytosolic) fraction and a ureadetergent soluble (cytoskeleton/membrane) fraction were obtained. Before protein separation by 2-dimensional gel electrophoresis (2-DE), sample contaminants were removed, and protein concentration in the extracts was measured. 18 Protein extracts of control platelets and thrombin-stimulated platelets obtained from animals treated without or with NOd were separated by 2-DE. 18, 19 Isoelectric focusing was performed using the Protean-IEF cell (Bio-Rad). Protein loads were applied on linear immobilized pH gradient strips and separated by 2-DE. Gels were developed by silver staining, according to Gharahdaghi et al, using a protocol that ensure compatibility with subsequent mass spectrometry analysis. 20 Each 2-DE run was at least repeated twice. Gels were analyzed for differences in protein patterns with the PD-Quest software (Bio-Rad). 21 Each spot was assigned a relative value that corresponded to the single spot volume compared with the volume of all spots in the gel, following background extraction. Normalization between gels was based on the total spot volume of all valid protein spots in each gel.
Protein spots of interest were excised from 2-DE gels and digested with sequence-grade modified porcine trypsin (Promega). Protein identification was performed by peptide-mass fingerprint using an Ettan MALDI-TOF Pro matrix-assisted laser desorption ionization/ time of flight mass spectrometer (GE-Healthcare) operated in delayed extraction/reflector mode. The peptide masses were searched against the National Center for Biotechnology Information nonredundant mammalian database using ProFound and confirmed using a Mascot search from Matrixscience, selecting the SwissProt database. Protein identification was based on the measurement of at least 10 peptides with a minimum of 50% matched peptides and coverage higher than 20%. Minimal expectation for valid identification was PϽ0.01 and PϽ0.05. 21
Western Blot Analysis
Western blot analysis was performed as previously described 22 using the following primary antibodies: mouse monoclonal antibody (mAb) anti-gelsolin (Abcam), a mAb anti-filamin A (Abcam), a mAb anti-14-3-3-␤ϩ (Abcam), a rabbit polyclonal antibody anti-Grb2 (Stressgen) or a goat polyclonal antibody anti-PI3KG (Novus Biologicals), a specific mAb against the serine 239 phosphorylation site of vasodilator-stimulated phosphoprotein (VASP) (46 kDa) (NanoTools), and a mAb antibody that recognizes VASP (46 kDa) and VASP phosphorylated at serine 157 (50 kDa) (clone IE273 Immunoglobe).
Confocal Microscopy
Paraformaldehyde-fixed washed platelets were permeabilized, blocked with bovine serum albumin, and incubated with the abovedescribed primary antibodies (see Western blot description) and the appropriate Alexa Fluor 488 IgG (HϩL)-labeled secondary antibodies (Molecular Probes). Negative controls of primary and secondary antibody labeling were run with each set of experiments. Labeled cells were examined in a Leica inverted fluorescence confocal microscope (TCS SP2-AOBS).
Statistical Analysis
Results were expressed as meanϮSEM. After testing for normal distribution and equality of variances with the Levene F test, the Student t test or ANOVA, as appropriate, was used to determine statistical significance for differences between treatments. A value of PϽ0.05 was considered significant.
Results

Platelet Function
Western blot analysis of total and phosphorylated VASP was performed to provide evidence that the in vivo NOd treatment had induced platelet inhibition. As shown in Supplemental Figure I , treatment with the NOd LA419 significantly induced VASP phosphorylation in Ser239 even in thrombinstimulated platelets (PϽ0.05). Thus, thrombin activation induced a significant decrease in phosphorylated VASP in platelets from nontreated animals (PϽ0.05), whereas it did not affect VASP phosphorylation in platelets from animals treated with NOd.
Platelet Proteomic Analysis
Differential proteomic analysis of cytosolic-and membrane/ cytoskeleton-enriched platelet fractions was used to investigate the coordinated inhibitory effect of NOd in thrombinactivated platelets. Tris-based buffer was used to solubilize cytosolic proteins, whereas the urea/thiourea-based buffer was used to solubilize hydrophobic proteins (cytoskeleton and membrane proteins). 14 Initially, we performed a first screening using a broad pH range (pH 3 to 10) in both Tris-soluble and urea/thioureasoluble fractions. Proteomic analysis detected in each fraction approximately 650 protein features (data not shown). Out of these, more than 60% were allocated in a pH ranging from 5 to 8, which led us to study the subproteomes in this pH range (Supplemental Figure II) . Average gels were obtained from 4 independent experiments (4 placebo-treated and 4 NOdtreated animals). Identified protein spots showed good correlation within the experimental error range of determined molecular weight (MW) and isoelectric point (pI) values with those predicted from their amino acid sequences. NOd treatment induced Ͼ2-fold changes in the expression pattern of 12 nonredundant proteins in the cytosolic subproteome and 10 proteins in the membrane/cytoskeleton-enriched fraction of thrombin-activated platelets. These proteins were involved in actin assembly, signaling, and metabolic activity, as summarized in the Table. The effects of NOd treatment on the proteomic signature of resting platelets (before thrombin stimulation) were in general minor (ϽϮ2-fold). Only cytoskeleton and cell shape related proteins (such as tropomyosin, tubulin, and filamin) were increased (Ͼ2.5-fold) in resting platelets from animals treated with NOd.
Among the different protein changes modulated by NOd treatment in thrombin-activated platelets, translocation of gelsolin and filamin A, 2 key proteins involved in actin dynamics and assembly, was prevented, and PI3K, Grb2 and 14-3-3, proteins involved in different activation signaling pathways, were inhibited. Therefore, for validation purposes, we focused our efforts to study the effect of LA419 on the expression pattern of these 5 proteins.
Effect of the NOd LA419 on Cytoskeleton Proteins
Gelsolin The severing and actin capping protein gelsolin (SwissProt accession number P20305; spot 1 in Supplemental Figure II) was identified in the cytosol and cytoskeleton/membrane fractions of resting and thrombin-activated platelets of both NOd-treated and untreated animals. Analysis by 2-DE showed that thrombin-activated platelets had higher gelsolin levels in the cytosol and lower in the urea-soluble fraction than control platelets ( Figure 1A) . Interestingly, these changes were not observed in thrombin-activated platelets from NOd-treated animals, indicating that NO prevented gelsolin mobilization from the platelet membrane to the cytosol on thrombin stimulation ( Figure 1A) . A similar trend was shown by Western blot analysis in 1-dimensional gel electrophoresis gels. Thus, gelsolin content significantly increased in the Tris-soluble fraction (PϽ0.005) and decreased in the urea/detergent-soluble fraction on thrombin stimulation (PϽ0.05), whereas the machinery for gelsolin translocation was blocked in platelets derived from NOd-treated animals ( Figure 1B) . To further elucidate the effect of NOd in gelsolin distribution, resting and thrombin-activated platelets were analyzed by immunofluorescence. In resting platelets, gelsolin mainly localized in membrane-like structures, whereas a pattern of diffuse positive signals distributed throughout the platelet cytoplasm was observed after thrombin activation. In contrast, this homogeneous labeling pattern was not seen when platelets from animals treated with the NOd were stimulated with thrombin because gelsolin remained in the membranes ( Figure 1C , see insets with magnifications).
Filamin A
Filamin A (SwissProt accession number Q96C61 for human) was detected by 2-DE as 2 clusters of 4 spots with MWs in the ranges 85 to 90 kDa (spots 7 and 9) and 70 to 75 kDa (spots 8 and 10). In both clusters, the spots were distributed in 2 series of different pI values (approximately 5.3 versus 5.6), presumably corresponding to different phosphorylated forms. Thrombin activation significantly changed the distribution pattern of Filamin A spots in the 70-to 75-kDa clusters. In thrombin-activated platelets, spots 9 and 10 showed an increase in the Tris -soluble fraction, whereas spot 7 showed a significant decrease (Figure 2A ). The increase in pI in filamin A spots on thrombin activation could be attributed to protein dephosphorylation. Thrombin-stimulated platelets from NOd-treated animals, however, showed a pattern similar to that of resting control platelets. Additionally, in the urea-soluble fraction, spot 9 decreased on thrombin-stimulation in control platelets but not in NOdtreated platelets (Figure 2A) .
Western blot analysis showed that in the cytosolic-enriched fraction, filamin A was significantly decreased in thrombinactivated platelets in the NOd group but not in the control group, whereas in the membrane/cytoskeleton-enriched fraction, the opposite pattern was observed (PϽ0.05, Figure 2B ). Confocal microscopy analysis also confirmed a differential distribution pattern of filamin in the platelets derived from NO-treated animals, with filamin A remaining in the cytoskeleton. Platelet activation delocalized filamin from the platelet membrane to the cytosol in control platelets. However, NOd treatment prevented this translocation, as seen in Figure 2C (see insets with magnifications).
Effect of NOd in Thrombin-Activation Signaling Proteins
Spot 23, with a pI of approximately 7.1 and a MW of 38 kDa, was identified as PI3K␥ by fingerprinting analysis in the cytosol subproteome of the porcine platelets. The low MW of spot 23 suggests that the identified protein refers to a regulatory subunit of the isoform PI3K␥ (p55PIK) (SwissProt accession number Q92569 for human). Spot 23 was consistently detected in the cytosol subfraction of platelets from NO-treated animals, under both basal and thrombin-activated conditions ( Figure 3A ), but its signal was very weak or under the detection level on thrombin-activation in the absence of the NOd. A spot with similar pI and MW was not detectable as PI3K␥ in the urea-detergent soluble fraction (data not shown).
Western blot experiments ( Figure 3B ) showed translocation of the PI3K␥ catalytic subunit to the urea/detergentenriched fraction in response to thrombin in the control group, but this effect was blocked in platelets treated with NOd. As shown in Figure 3B , PI3K levels in the urea/ detergent-soluble fraction were significantly lower in resting platelets than in thrombin-activated platelets from the group not treated with the NOd (PϽ0.05). In contrast, this pattern was not observed in thrombin-activated platelets from the NOd-treated group. Accordingly, immunofluorescence analysis showed a cytoplasmic distribution of PI3K in resting platelets that translocated to the membrane on thrombin activation in platelets derived from placebo-treated animals but not in NOd-treated platelets ( Figure 3C , see insets with magnifications). 
14-3-3, or YWHAZ (SwissProt accession number
P63104 for human), was identified only by matrix-assisted laser desorption ionization/time of flight analysis in the Tris-soluble fraction, where it was found as a series of 3 spots (spots 24, 25, and 26), with a MW of approximately 30 kDa and a pI between 4.80 and 4.90. Thrombin activation significantly changed the 14-3-3 distribution pattern. Thus, spots 25 and 26 were significantly decreased to under the detection limit in thrombin-activated platelets from animals treated with placebo ( Figure 4A , arrowheads). This effect, however, was partially prevented in platelets from NOd-treated animals activated with thrombin. Spot 24, presumably the most phosphorylated 14-3-3-, was strongly detected in platelets from control animals (without NOd treatment), independently of thrombin activation ( Figure 4A, control and placebo treated) , whereas the spot intensity was Ͼ2-fold decrease in platelets from NOd-treated animals (note differences in pattern distribution between spots 24, 25 and 26 for control, placebo treated, and NOd-treated groups in Figure 4A ). Western blot analysis showed that thrombin induced a significant decrease of 14-3-3in the Tris-fraction (PϽ0.05) and an increase, although not a significant one, in the urea-soluble fraction of thrombin-activated platelets in the control group but not in the NOd-treated group ( Figure 4B) . Similarly, we observed by immunofluorescence a higher expression of 14-3-3-in the platelet membrane in thrombin-activated platelets in the control group but not in the NOd group ( Figure 4C , see insets with magnifications).
Spot 21 was identified as Grb2 (SwissProt accession number B6E241). As observed by 2-DE ( Figure 5A ), thrombin stimulation induced Ͼ3-fold increase in Grb2 expression in the urea-fraction of platelets from control placebo animals, but not in platelets from NOd-treated animals. This effect was also evident by Western blot analysis ( Figure 5B ). Interestingly, Western blot analysis revealed that thrombin induced an increase in the ureasoluble fraction of Grb2 in platelets from placebo animals ( Figure 5B ), whereas Grb2 levels in thrombin-stimulated platelets from NOd -treated animals remained similar to those in resting platelets (PϽ0.05, Figure 5B ). The effect of NOd on Grb2 localization was also analyzed by confocal microscopy. In nonactivated platelets, Grb2 appeared to be diffused in the cytoplasm region. In contrast, on thrombin stimulation, Grb2 distribution showed a scatter pattern localized in the platelet surface. Interestingly, activated platelets from NOd-treated animals showed a distribution pattern of Grb2 similar to control platelets, 
Discussion
The present study was designed to identify novel targets of NO inhibition on platelet activation. We have previously demonstrated in vivo important antiischemic and antithrombotic properties, without adverse effects, of a novel organic nitrate (LA419) containing a thiol group, 14, 15 establishing that LA419 exerts its effects via cGMP inhibition. The platelet inhibitory effects of the NOd have been confirmed in the experimental setup of the current study by the significant increase in platelet level of VASP Ser239 phosphorylation in NOd-treated platelets. However, there are additional potential effects that may likely contribute to enhance platelet inhibition. Using a proteomic approach, we identified up to 21 nonredundant proteins, relevant for actin dynamics, signaling, and metabolic activity of platelets, involved in the antithrombotic effects of LA419. The differential analysis of cytosolicand membrane/cytoskeleton-enriched platelet subproteomes of thrombin-activated platelets allowed us to investigate the effects of NO-treatment on 5 key proteins involved in inside-outside signaling and cytoskeleton dynamics during platelet activation ( Figure 6 ). It is important to note that the urea-enriched fraction not only contains the external membrane fraction but also the cytoskeleton fraction. Therefore, our observed protein translocations represent protein movements from soluble to insoluble fractions.
One of the earliest responses of platelets to thrombin stimulation results in the activation and translocation of PI3K to the cytoskeleton at sites of integrins dependent focal adhesions. Here, by two-dimensional electrophoresis, we found changes in a PI3K␥ subunit, molecule that signals to a regulatory subunit (p55PIK) of this protein. Up to now, small size (MW of 43 to 55 kDa) regulatory subunits for PI3K␥ have been reported in cell lines 23, 24 and primary tumor cells. 25 To our knowledge, the presence of the regulatory PI3K␥ subunit p55PIK has not been previously shown in platelets. Once translocated, PI3K is thought to have a key role in cytoskeleton reorganization that accompanies irreversible platelet aggregation. 26 In in vitro experiments, NO was shown to inhibit thrombin receptor-activating peptide-induced PI3K activity. 27 Indeed, we observed an increase in PI3K␥ isoform expression in the soluble fraction in thrombin-activated platelets from NOd-treated animals compared with thrombinstimulated platelets from untreated animals. Thus, NOd treatment prevented thrombin-induced PI3K␥ translocation to the membrane and inhibited platelet aggregation.
In resting platelets, actin filaments are stabilized by VASP, which protects actin filaments from the severing effects of gelsolin. 28 An initial step in platelet shape change implies the disassembly of actin filaments, which are then reorganized into new actin structures. Dissociation of gelsolin from barbed ends and further actin filament polymerization are dependent on intracellular Ca 2ϩ rise 7 (either through phospholipase C-␤ pathway 29 or by opening calcium channels) and on PI3K activity. 30 We have shown in our study that gelsolin and filamin A are maintained in the cytoskeletonenriched fraction after thrombin activation in LA419-treated platelets, suggesting that NO interferes with the translocation machinery, restricting the access of barbed end capping proteins and thus preventing the interaction of filamin with the GPIb-IX-V complex. Filamin and GPIb-IX-V interaction is essential in the regulation of platelet shape and spreading and in the anchoring of the receptor complex to the membrane skeleton. 31 14-3-3 proteins serve as adaptors in recruiting and regulating signaling molecules involved in signal transduction across transmembrane receptors. Interaction of 14-3-3 proteins with signaling molecules can localize, activate, inhibit, or stabilize target molecules. 32 The association between PI3K and 14-3-3-with GPIb-IX serves to promote the rapid translocation of these signaling proteins to the activated cytoskeleton, thereby regulating the formation of 3-position phosphoinositide signaling molecules in this subcellular compartment. 33 Recent studies suggest that 14-3-3-activity and target specificity depend on its phosphorylation state. 34, 35 In this respect, the differential 14-3-3-proteomic profile found in thrombin-stimulated platelets from animals treated with NOd may indicate a new pathway of platelet inhibition. In addition, we observed in our study that 14-3-3-decreased in the cytosolic fraction in thrombin-activated platelets derived from placebo animals but not in NOd-treated animals. We can then hypothesize that NO also prevents 14-3-3 mobilization in a PI3K-dependent or -independent manner. Indeed, in line with these findings, it has been shown that cGMP-and cAMP-dependent protein kinases inhibit binding of 14-3-3 to the GTPase-activating protein Rap1GAP2, regulating integrin activity and cell adhesion. 36 Finally, the adaptor protein Grb2 is a cytosolic protein that links stimulated membrane receptors to the Ras-signaling pathway, leading to cell proliferation or differentiation. 37 In nonstimulated cells, Grb2/Sos or Grb2/Cbl exists as a cytoplasmic preformed complex. On activation, this complex translocates to the recruitment of other proteins and propagates the signal to downstream transducers, such as Ras and mitogen-activated protein kinases. Unlike Cbl and SOS, p85/PI3K associates with Grb2 regardless of the presence or the absence of the peptidimer conjugate, indicating that a phosphotyrosine of Grb2 may directly associate with PI3K-Src homology-2 domains after platelet activation. 38 We found in our study that Grb2 significantly increased in the membrane/cytoskeleton-enriched fraction on thrombin stimulation in platelets from the placebo group. Moreover, platelets from NOd-treated animals that were activated with thrombin showed similar levels of Grb2 in the membrane/ cytoskeleton subproteome compared with control platelets, suggesting that NO might block the first step of platelet activation in the Ras pathway. Indeed, RAS-extracellularsignal-regulated kinase (ERK) signaling pathway components [ie, RAS/RAF/mitogen-activated protein kinase/ERK kinase (MEK)/ERK] play a key role in platelet activation. 39 In summary, we previously showed that oral administration of NOd inhibits platelet mural thrombosis on severely damaged vessel wall without hypotensive effects. 14 Here, by means of differential platelet subproteome analysis, we have identified novel target proteins involved in the inhibitory effect of NO in platelets. Indeed, platelets from treated pigs have shown to be irresponsive to the effect of thrombin. NO treatment prevented the translocation of the signaling proteins PI3K, 14-3-3-, and Grb2 to the membranes and maintained filamin A and gelsolin in the cytoskeleton fraction. Figure 6 . Scheme for NO targets related to actin dynamics, platelet shape change, and inside-out signaling events in thrombinstimulated platelets. Shown are some of the main players linking thrombin activation via the G proteins to the induction of actin dynamics, degranulation and inside-out activation of integrins. In "resting" states, platelet shape and size is stabilized by anchorage of the actin cytoskeleton to the glycoprotein Ib (GPI)b␣ cytoplasmatic domain through filamin. (The cytoplasmatic domain GPIb␣ anchors the actin filaments to the membrane through filamin stabilizing platelet shape and size in "resting" states.) Thrombin activation induces filamin dissociation from GPIb␣ through a 14-3-3-and phosphatidylinositol 3-kinase (PI3K)-dependent process and "switches on" platelet shape change. PAR indicates protease-activated receptor; G, G protein; PLC, phospholipase C; PIP2, phosphatidylinositol 4,5bisphosphate; IP3, inositol 1,4,5-trisphosphate; ROCK, RhoA kinase; MLCP, myosin light-chain phosphatase; MLCK, myosin light-chain kinase; MRLC, myosin regulatory light chain; MRLC-P, phosphorylated MRLC; GRB2, growth factor receptor-bound protein 2; Shc, adapter protein; NO, nitric oxide. port. Dr Vilahur is recipient of a contract from the Spanish Ministry of Science and Innovation (MICINN, RyC-2009-5495).
